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Objective 
The efficacy for primary orthotOPIC liver transplantation of a new immunosuppressive agent, FK 
506 (tacrotimus. Prograf. Fujisawa USA. Deerfield. IL). was determined. 
Summary Background Data 
After 3 years of preclinical research. a clinical Inal of FK 506 for orthotopic liver transplantation 
was begun In February 1989. first as a rescue therapy for patients With intractable relection With 
conventional immunosuppression. then as a primary drug. 
Methods 
Between August 1989 and December 1993. 1391 recipients (1188 adult and 203 pediatric) of 
primary liver allografts were treated with FK 506 from the outset. Results from these patients were 
analyzed and compared with those of 1212 histoncal control patients (971 adult and 241 
pedlatnc) given cyclosponne-based immunosuppression. 
Results 
Actuanal SUrviVal at 4 years was 86.2% With FK 506 versus 65.5% With cydosponne In the 
pedratnc patients (p < 0.0000) and 71.4% versus 65.5% in the adults (p < 0.0005). The need for 
retransplantatlon was reduced Significantly for FK 506 patients. Four·year graft SUrvIVal was 
77.0% With FK 506 versus 48.4% With cyclosponne In the pedratnc patients (p < 0.0000). and 
61.9% With FK 506 versus 51.4% With cyclosponne In the adult reCIPients (p < 0.0000). 
RegreSSion analysis revealed that reductions In mortality or graft loss from uncontrollable 
reJ8Ctlon. sepSiS, technlC8l failure, and recurrent onginalliver disease were responSible for tM 
Improved results With FK 506 therapy. 
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Conclusions 
FK 506 is a potent and superior immunosuppressive agent for orthotopic liver transplantation. 
FK 506 (tacrolimus, Prograf, Fujisawa USA, Deer-
field, IL), the first new baseline immunosuppressive drug 
to be certified by the FDA in 1 I years, has been available 
in pharmacies in the United States since April 1994. Af-
ter 3 years of preclinical research in Chiba,l-6 Pitts-
burgh,7-12 Cambridge,l3-IS and elsewhere, the drug was 
first used clinically in February 1989, to successfully treat 
patients at our center who were undergoing intractable 
rejection of their liver allografts despite maximum 
cyclosporine-based therapy. 16 A few months later, exten-
sive trials were begun with FK 506 as the primary immu-
nosuppressant for recipients of all of the commonly 
transplanted organs. 17.11 
We report our experience in the 1391 consecutive 
adult and pediatric recipients of primary liver allografts 
who were treated from the outset with FK 506 between 
August 18, 1989, and the end of 1993. The first 120 of 
these patients were reported at the American Surgical 
Association in 1990.17 The subsequent case collection in-
cluded an internal cohort of 79 optimum risk patients 
who participated in a randomized trial ofFK 506 versus 
cyclosporine, which has been reported elsewhere. 19 How-
ever, the current analysis is of all cases, totaling 2.6 times 
more than the combined number in the recently com-
pleted American and European multicenter trials, which 
have not been published yet. We describe the impact of 
this drug on our program. and mention some of the man-
agement principles that have been found to be applicable 
to the transplantation of other organs. 
METHODS 
case Material 
The heterogeneous indications for operation. patient 
ages. and patient degrees of urgency according to United 
Network for Organ Sharing (UNOS) criteria are summa-
rized in Table I. Infants and children accounted for 203 
recipients. in whom the most common diagnosis was bil-
iary atresia. Almost 213 of the 1188 adults had postne-
crotic cirrhosis with various etiologies. 
To judge the impact of FK 506 on our program. the 
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patient and graft survivals in our historical experience 
was reviewed retrospectively to the first case in 196320 
and stratified according to the principal advances that 
ultimately made liver transplantation practical: 1) 1963-
1979 (n = 168)-immunosuppression was with azathio-
Table 1. INDICATIONS AND UNOS STAnJS 
FOR UVER TRANSPLANTATION IN 1391 
FK506 PATIENTS AND 1212 
CYCLOSPORINE PATIENTS· 
Patients f1(506 CycIoaporine 
No. of patients 1391 1212 
No. of transplants 1582 1549 
PrImary transplantation 1391 1212 
Retransptantation 191 337 
Median follow-up: mos (range) 29.6(3-55) 68.3 (25-99) 
Pediatric ( < 18 yrs) 
NI.mber of patients 203 241 
Melnage± SO 5.4±5.5 4.8 ± 4.8 
Indicabonst 
Fuminant failw-e 13 (6.4"0) 18 (7.5%) 
Poatnecrotic CirrhOSIS 21 (10.3%) 18 (7.5%) 
Mary atresIa 99(48.8%) 138(57.3%) 
MetaboOc disease 21(13.3%) 31 (12.9%) 
PrImary malignancy 1 (0.5%) 4(1.7%) 
Other 42(20.7%) 32(13.3%) 
UNOS Status; 
1 3 (1.5%) 11 (6.1%) 
2 51(28.1%) 52(28.9%) 
3 72(35.5%) 41(26.1%) 
4 71 (35.0%) 70(38.9%) 
AdLit (> 18 yrs) 
No. of patients 1188 971 
Mean age :t SO SO.1 ± 12.0 46.1 ± 12.6 
Indicabons 
Fuminant failure 30(2.5%) ~E4KR%F 
PoatnecrotIC CIrrhoSIS 749(63.0%) 508(52.3%) 
CholestatJC disease 200(16.8%) 229(23.6%) 
MetabolIC disease 38(3.2%) 39(4.0%) 
Primary maligtI8nCV 89(7.5"0) 69(7.1%) 
Other 82(6.9%) 82(8.4%) 
UNOS status; 
1 5(0.4%) 56(6.8%) 
2 189(15.9%) 158(18.9%) 
3 476(40.1%) 354(42.8%) 
4 518(43.6%) 261 (31.6%) 
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prine (or cyclophosphamide), prednisone. and usually 
antilymphocyte globulin; this original series I had 170 
patients.21 2 of whom were excluded from the current 
analysis because they underwent simultaneous renal 
transplantation: 2) 1980-1987 (n = 623)-immunosup-
pression was with cyclosporine and prednisone. to which 
azathioprine. antilymphocyte globulin (or OKT3) were 
added as clinically indicated; Eurocollins solution was 
used for organ preservation; 3) 1987-1989 (n = 1212)-
same as the previous advance (2). but organ preservation 
was with University of Wisconsin (UW) solution; 4) 
1989-1993 (n = 1391)-same as the previous advance 
(3), but with FK. 506 instead of cyclosporine. 
For a more detailed comparison between the previous 
and current regimens, the 1212 patients in Group 3 were 
analyzed in the same detail as the 1391 patients in Group 
4. The collective case profiles were comparable except 
for trends in the later period for older age candidates, 
a higher percentage of postnecrotic cirrhosis, and more 
extremely ill patients (Table 1). 
Immunopathologic and Surgical 
Procedures 
With rare exceptions, ABO identical donors were 
used. Human lymphocyte antigen ma,tching was ran-
dom. Because Iymphocytotoxic results became available 
after the fact. 10% oflivers were transplanted across pos-
itive crossmatches.22 The panoply of variations used for 
the donor operations and transplant operations has been 
described elsewhere.21 Needle biopsies were taken fre-
quently to determine the cause of graft dysfunction or 
routinely during the early part of the study. The histo-
pathologic criteria of rejection have been standardized 
thoroughly.23 
Immunosuppression 
FK505 
The general policies were the same as reponed to the 
American Surgical Association in 199017 and were sim-
ilar to those developed previously for cyclosporine.21 The 
nephrotoxicity. neurotoxicity. and diabetogenicity of 
FK 506 were delineated and shown to be dose related 
from the OUtset.I7.II.l4 In addition. it was promptly 
learned that defective metabolism of the drug when there 
was hepatic graft dysfunction necessitated downward 
dose adjustments. 17.:z,.26 Consequently. dose revisions 
were guided by the balance between rejection control. 
toxicity. and trough plasma levels ofFK 506. which were 
measured with an enzyme immunoassay techninue~T 
and targeted to 1 ng/mL. For the first cases. the initial 
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F9n 1. Effect of three different perioperative dosing schedules of FK 
508 In pallents selected for analysts beCause they did not have pnHXisl· 
Ing renal dysfunction or glucose intolerance. and because !heir hepatic 
gafts functioned promptly. Intravenous iI1duction doses were 0.15, 0.10, 
and 0.05 mg/kg/day in Groups 1, 2. and 3 respectively, and starting oral 
doseS were 0.3, 0.2-0.3. and 0.2 mg/kg/day. 'p < 0.05 means group 
differences were significant. 
intravenous doses were 0.1 5 mg/kg/day given in divided 
4--hour boluses; however, in May 1990, these were re-
duced to 0.10 mg/kg/day and administered by continu-
ous infusion until oral alimentation was resumed. When 
these doses still were found to be toxic for a significant 
number of patients. intravenous induction was further 
reduced in August 1991 to O.OS mg/kg/day. The oral 
doses that originally were 0.3 mg/kg/day also were scaled 
down commensurately. 
The drift to more conservative dosing is illustrated in 
Figure I in subgroups of high-. medium-. and low-dose 
recipients who were selected for special study because 
they were free of confounding factors. Conditions for in-
clusion were preoperative serum creatinine < 1.5 mg%, 
preoperative fasting blood sugar < I SO mg%. and good 
early hepatic graft function. The results of such studies 
improve management policies for more complex cases. 
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figure 2. Average FK 506 doses/kg and 12-hour trough plasma concen-
trations In pediatnc and adult liver reapients dunng the first postoperatIVe 
year. 
They showed that avoidance of the early postoperative 
FK 506 plasma spike essentially eliminated the toxicity 
problems that bedeviled our first patients and those sub-
sequently entered into the early multicenter trials. Im-
ponantly, the incidence of rejection was not increased as 
the FK 506 doses were diminished (Fig. I). The penalty, 
however, was the need for compensatory increases in 
prednisone doses and a consequent statistically greater 
incidence of hyperglycemia (Fig. I, second panel from 
bottom) until these doses could be weaned. 
On a body weight basis. children required average FK 
506 doses 1.52 times greater than those of adults to 
achieve equivalent plasma trough levels. In both age 
groups, progressive weaning to lower doses throughout 
the first year and subsequently of FK 506 (Fig. 2) and 
prednisone made management easier. reduced toxicity, 
and assured a high quality ofHfe. 
Other Drugs 
In the first cases. 1 g of methylprednisolone was given 
intravenously to adults during operation, followed by a 
5-day burst of methylprednisolone, which was staned at 
200 mg on the first day and reduced daily in 40 mg steps 
until 20 mgjday was reached on postoperative day 6. Ap-
propriately lower doses were given to infants and chil-
dren. During a second phase. treatment was begun with 
20 mgjday methylprednisolone. a poticy still followed on 
a discretionary basis with some fragile recipients. How-
ever. the high-dose steroid burst at the beginning has 
been shown to be effective prophylaxis in the event of a 
positive Iymphocytotoxic crossmatchll and is our cur-
rent routine standard because the results of the immuno-
logic tests usually are not available at the time of opera-
tion. With either kind of induction. prednisone doses 
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were weaned over several months and eventually 
stopped if there was no evidence of rejection. 
Oinical diagnoses of rejection episodes were con-
firmed by needle biopsy. If they were unresponsive to in-
creasing the maintenance doses ofFK 506, the rejections 
were treated with a single leg bolus of methylpredniso-
lone or hydroconisone for adults or with smaller quanti-
ties for children. If rejection persisted, additional steroids 
were given, a 3- to 5-day course of 5 or 10 mg/day OKT3 
was considered. and in a few cases, azathioprine was 
added. 
The Cross-Over Phenomenon 
With the first clinical use of FK 506, it was notedI6•29 
and soon widely confirmed that the drug had a remark-
able ability to halt and reverse liver rejection that was 
intractable, despite optimal cyciosporine-based therapy. 
After rescue, most of these patients were liberated from 
dependence on high doses of steroids. This prima Jacie 
evidence of superiority raised troubling ethical issues 
about randomized trials in such a high-risk population. 
These same questions of propriety had been raised in 
1980, when cyciosporine replaced azathioprine.3O and a 
decade later, patient demand for FK 506 and the deter-
mination of the physicians and surgeons to give what 
they believed to be optimal treatment generated tumul-
tuous conflict with the Institutional Review Board, 
which had mandated such a trial. As a compromise, a 
trial was begun, but only for low-risk patients. 19.31 In the 
meantime, a large scale switch was occurring from 
cyclosporine to FK 506. The crossover eventually to-
talled 437 patients in our program alone. with an esti-
mated 1000 examples elsewhere in the United States. In 
1991, an interinstitutional advisory group, impaneled by 
the University of Pittsburgh as a watchdog safeguard for 
patients' rights. recommended discontinuance of the 
randomized trial. and with the concurrence of the Insti-
tutional Review Board and the Food and Drug Admin-
istration (FDA), this was done. With freedom of patient 
choice in effect. FK 506 replaced cyclosporine (Fig. 3). 
Data Analysis 
Patient survival was calculated from the date of trans-
plantation until patient death. and graft survival was cal-
culated from the date of transplantation until re-
transplantation or patient death. Survival curves were 
generated using the life table method and were compared 
using the log rank (Mantet-Cox) test. Cox's proponionai 
hazards model was used to analyze different causes of 
monality and different causes of graft failure in the pa-
tients from Group 3. who received cyclosporine. com-
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pared with those of Group 4, who received FK 506. 
Differences in group means were tested using the one-
way analysis of variance; differences in proportions were 
tested using Pearson's chi square test of association. A p 
value < 0.05 was considered statistically significant. 
RESULTS 
Survival 
Patient survival during the 30-year history of clinical 
liver transplantation improved in leaps rather than steps 
(Fig. 4). The greatest single increment was the advent of 
cyclosporine, 21.32 which was first given to a liver recipient 
by Calne et al.33 A small additional gain (NS, p = 0.(8) 
came with the introduction of UW solution (Group 3). 
Further improvement relative to what had been achiev-
able previously already was evident at the time of our 
presentation in 1990, at the American Surgical Associa-
tion, of the first 120 liver recipients who represented our 
learning curve. With >4 years follow-up, 13 (86.7%) of 
the 15 original pediatric recipients and 81 (77.1 %) of the 
105 adults remain well. All of the survivors are working, 
in school, or fully functional in home life. The more than 
tenfold expansion of this experience has confirmed the 
initial conclusions. 
Pediatric Recipients 
Infants and children of all ages, with all diagnoses. and 
of all urgency categories, including the high-risk UNOS 
4, had an improved prognosis (Table 2). 
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FIgure 4. Patient sUl'Vival during the 3Q·year history of the program at the 
UniversrtJes of Colorado (1963-1980) and Pittsburgh (1981-1993). The 
eras were defined by maJOl' improvements (see text). The dates of case 
aa:ruaI from bottom to top CUlVes were 1963-1979 (Group 1), 191n-1987 
(Group 2). 1987-1989 (Group 3). and 1989-1993 (Group 4). Groups 3 
and 4 had significantly different slroIMIl (p < 0.0000). AZA - azathiOpnne. 
CyA-EC '" cycIosporine, EurOCOIlins SOlution for preservation. CyA-vN -
cycIosporine. University of WisconSIn solution for preservation, FK 506 -
taaaIimus. University of WIsconSIn solution for preservation. 
Adult Recipients 
An improvement also was observed in the adults that 
was significant overall (p < 0.0005), evident in all eight 
subgroups, and significant in four of the eight (Table 3). 
However, the large survival gap in the patients with hep-
atitis B virus was primarily a result of avoidance ofhep-
atitis E antigen-positive recipients in the FK 506 era. 
Graft Survival 
The survival slopes in the different eras and their de-
gree of separation from each other were parallel to those 
of patient survival. but approximately I ()% lower (Fig. 
5). The higher patient survival reflected the benefit of reo 
transplantation. The improvement of graft survival 
when UW solution was added to cyclosporine-based im-
munosuppression (Group 2 VS. Group 3) was significant 
(p - 0.0057), as was the funher improvement with FK 
S06 (Group 3 VS. Group 4; p < 0.0000). 
Causes of Death 
The first 3 months after liver transplantation has long 
been known to be the period of principal mortality (Fig. 
4). During this time. the same kinds ofletha! complica-
tions were seen in the cyclosporine and FK 506 groups, 
but they occurred less frequently with FK S06 in aU 
302 Todo and Others Am. pwgKK~ 1994 
Table 2. SURVIVAL OF PEDIATRIC PATIENTS UNDER FK506 VS. CYCLOSPORINE 
AFTER UVER TRANSPLANTATION .. 
N 3Mo 8Mo 
AI patients 
FK506 203 91.1 89.6 
eYA 241 74.2 72.2 
Age 
0-2yrs 
FK506 86 88.3 85.9 
CYA 98 67.3 64.2 
2-12yrs 
FK506 76 90.7 89.4 
CYA 115 79.1 78.2 
12-18 yrs 
FK506 41 97.5 97.5 
CYA 28 78.5 75.0 
Indicabon 
BUiary atreSia 
FK506 99 91.9 88.8 
CYA 138 73.1 71.7 
Metabolic disease 
FK506 27 96.3 96.3 
CYA 31 SO.6 SO.6 
UNOS4 
FK506 71 84.5 83.0 
CYA 70 68.5 65.7 
• ~ test be'-FI< group and cydosponne group. 
seven of the cause of mortality categories of both pediat-
ric and adult cohons (Table 4). The three categories in 
which the differences were statistically significant were 
technical failure (most commonly hepatic artery throm-
bosis or bile duct complications). sepsis. and the um-
brella of immunologic reason. which included rejection. 
graft versus host disease. and post-transplant Iympho-
proliferative disorders. 
In the 4-year postoperative perspective. the same three 
factors were identified. By Cox regression analysis. the 
relative risk of fatal technical complications or sepsis in 
children was more than four times higher with 
cyciosporine (Table 5). For adults. immunologic reason. 
sepsis. and disease recurrence (most commonly malig-
nancies or hepatitis) ranged from 1.56 to 1.9S times 
higher with cyciosporine than with FK 506 (Table 5). 
Incidence and Causes of 
Retransplantation 
With FK 506. reuansplantation was required in 9.9% 
of the pediatric recipients treated with FK 506 compared 
with 22.8% in those treated with cyclosporine. The lower 
SUrvivel (Of.) 
1 Yr 2Yr 4Yr pVelu.· 
88.5 88.5 86.2 0.0000 
71.3 68.0 65.5 
85.9 85.9 82.4 0.0003 
62.2 59.1 58.1 
88.0 88.0 85.9 0.0418 
78.2 75.6 71.3 
94.9 94.9 94.9 0.0024 
75.0 67.8 67.8 
88.8 88.8 87.3 0.0004 
70.2 68.8 66.6 
91.8 91.8 0.1763 
SO.6 SO.6 n.4 
83.0 83.0 78.0 0.0132 
64.2 60.0 60.0 
rate with FK 506 was accounted for mainly by decreased 
rates oftechnica1 failure and irreversible rejection (Table 
6). In the 4-year perspective. the Cox regression analysis 
showed the same thing (Table 7). 
In adults. the retransplantation rate during the first 3 
months with FK 506 compared with cyclosporine was 
9.8 versus 13.7%. with technical failure and rejection ac-
counting for most of the difference. By Cox regression 
analysis. the risk of retransplantation because of rejec-
tion over a 4-year follow-up was 2.4 times greater with 
cyclosporine than with FK 506. Retransplantation for 
recurrent disease had a 3.5 times greater risk with 
cyciosporine than with FK 506; however. this was due 
to the same avoidance of E antigen-positive candidates 
described under cause of mortality (Table 3). 
DISCUSSION 
Although FK 506 and cyclosporine are chemically un-
related. each with a specific cytosolic binding site of 
different molecular weight. J4.1' both drugs block the im-
mune response by preventing the transcription of early 
T-cell activation genes. J6 Both also are nephrotoxic. neu-
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Table 3. SURVIVAL OF ADULT PATIENTS UNDER FK506 VS. CYCLOSPORINE 
AFTER LIVER TRANSPLANTATION 
Survival (%) 
N 3Mo 8Mo 1 Yr 2Yr 4Yr pValue' 
All patients 
FK506 1188 89.7 86.6 82.1 77.7 71.4 0.0005 
eVA 971 83.7 79.4 76.8 71.8 65.3 
Age 
18-60yrs 
FK506 899 91.6 88.5 84.4 79.9 74.1 0.0003 
eVA 837 84.4 80.5 n.9 73.0 66.7 
>60yrs 
FK506 289 83.9 eo.6 75.1 70.9 61.2 0.1219 
eVA 134 79.1 72.3 70.1 64.9 56.7 
Indication 
Non·A. non·8 CirrhOSIS 
FK506 225 89.1 86.7 80.5 74.3 73.3 0.5972 
eVA 179 84.9 79.8 77.6 75.4 72.0 
AlcoholIC cirrhosis 
FK506 268 90.9 87.4 84.5 81.3 72.4 0.1344 
eVA 169 83.4 80.4 79.2 75.1 66.3 
HB cirrhosIS 
FK506 95 91.5 90.4 83.3 71.8 68.9 0.0030 
CYA 68 75.0 61.6 63.2 52.9 48.5 
Primary biliary cIrrhosis 
FK506 108 88.7 88.8 84.7 83.5 83.5 0.4656 
CYA 131 87.5 85.4 83.2 81.7 76.3 
Primary sclerosing cholangitis 
FK506 88 100.0 98.8 91.5 96.0 91.4 0.0158 
CYA 86 91.6 89.5 81.2 83.1 76.4 
UNOS4 
FK506 518 86.5 83.3 71.5 73.9 68.1 0.0002 
CYA 261 77.7 72.0 67.4 62.4 55.2 
• Str.rivaI rales -.t computed USIng the ~fe table method. and P value by the 1Og-rank lest. 
rotoxic. and diabetogenic.17.IS.14 In addition. the two 
drugs are powerful growth factors. They are hepato-
trophic because they augment hepatic regeneration.37•31 
and they prevent the hepatocyte atrophy and organelle 
injury caused by Eck's fistula.39.40 However. the growth 
effects of gingival hyperplasia. facial brutalization. and 
hirsutism of cyclosporine are not caused by FK 506. and 
the drug is associated with a lower incidence ofhypcnen-
sion and hypercholesterolemia.I,.ls 
Although the preceding profiles were not identical. the 
similarity of effects of two such diverse agents was per-
plexing until their mechanisms of action were clarified 
with molecular studies. These revealed that cyclosporine 
and FK 506 are essentially inactive "prodrugs" whose 
cytosolic binding immunophilins (cyclophilin and 
FKBP t 2. respectively) also are inen in isolation.39 How-
ever. the cyclosporine-cyclophilin and FK 506-FKBP 
complexes activate a common target. phosphatase 
calcineurin. which modifies the transduction of calcium 
dependent signals from the surface T-cell receptor to the 
nucleus.J9-4· The immunophilins are found in all cells 
and are suspected by related mechanisms to panicipate 
in the modulation of multiple immunologic. endocrino-
logic. growth control. and chaperone-mediated path-
ways.·· ..... l ThUs. there was an explanation for the com-
mon pattern of the pleotropic effects. 
Similar mechanisms notwithstanding. the clinical per-
formance of FK 506 has been superior to cyclosporine. 
In our :lOOned randomized liver transplantation 
trial. lUI as in randomized trials conducted in multiple 
European and American centers. crossover from 
cyclosporine to FK 506 because of intractable rejection 
(but not vice versa) was a common event that frequently 
prevented death or the need for retransplantation of the 
patients begun on cyclosporine. With anaiyses by "intent 
to treat." patient and graft survival was similar on both 
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treatment limbs but never inferior with FK 506. How-
ever, this parity reflected the rescue of a significant num-
ber of patients classed for analysis as cyclosporine "suc-
cesses," in whom treatment had been changed perma-
nently to FK. 506. The superiority of FK 506 in 
randomized single-center trials of renal'" and lung trans-
Table 4. CAUSE AND INCIDENCE OF 
MORTAUTY IN FKS06 PATIENTS AND 
CYCLOSPORINE PATIENTS WITHIN 3 
MONTHS AFTER UVER TRANSPLANTATION 
p 
FK506 Cyclosporine Value 
Pediatnc patients 
No. 01 patients 203 241 
No. 01 mortalities 18 (8.9%) 62(25.7%) 0.0001 
causes 
T ecnnicalfaillle 6(3.0%) 27 (11.2%) 0.0010 
SepsIs 1 (0.5%) 11 (4.6%) O.ooeo 
ImmunOSupj:)I'8SSIOf1 related 1 (0.5%) 8 (3.3o/g) 0.0350 
ExtrahepallC event 3(1.5%) 7(2.9%) 0.3130 
Disease recurrence 0 1 (0.4%) 03580 
Grift failure 7(3.4%) 8(3.3%) 0.9400 
Other 0 0 
AU patients 
No. of patients 1188 971 
No. of mortalltJes 119(10.1%) 158(16.3%) 0.0010 
causes 
Technlcalfadure 22 (1.9%) 42 (4.3%) 0.0007 
Sepsis 33 (2.8%) 41 (4.2%) 0.0660 
immunosuppresSIOn related 9(0.8%) 15(1.5%) 0.0830 
Other 1 (0.1%) 4(0.4%) 0.1150 
Graft failure 33(2.8%) 35(3.6%) 0.2740 
Disease recurrence 1 (0.1%) 2(0.2%) 0.4500 
ExtrltlepatlC event 20 (17"0) 19(2.0%) 06350 
piantation4S also was obscured by minimizing the cross-
over factor. Rather than perpetuate this artifact of inter-
pretation, we have analyzed the effect that the drug has 
had on the welfare of the patient population in our pro-
gram. 
Based on our participation and observation in all pre-
vious transitions in the field, and influenced by the expe-
rience reported here, we believe that FK. 506 will sup-
plant cyc1osporine as the principal baseline drug for 
transplantation of the liver and other organs. Aside from 
the quality of life issues favoring FK 506 that have been 
reported in detail elsewhere-most hinging on the ass0-
ciated lower need for steroids and fewer cosmetic side 
effects-it has permitted a reduction in global monality, 
either when used up front or to rescue therapeutic fail-
ures of the previous best regimen. The dramatic way in 
which better immunosuppression changes the mortality 
and "need for retransplantation" profiles also was seen 
in 1980, with the advent of cyc1osporine. The three cate-
gories most affected then were the same as with the later 
transition from cyc1osporine to FK 506-rejection, sep-
sis, and technical failure. 
The rubric of technical failure can mean different 
things to different people. The best example is hepatic 
anery thrombosis, which we have categorized for 30 
years as "technical failure" because the surgeon's poor 
performance always is a theoretical possibility. However, 
Makowka et al .• 46 Samuel et al.,·7 and many others have 
shown that this complication is associated with multiple 
nontechnical factors, of which incompletely controlled 
rejection is thOUght to be a major one. Furthermore, 
most mechanical complications can be indirectly attrib-
utable to or aggravated by excessive immunosuppression 
(particularly prednisone). Once a seam is opened in the 
fabric of the finished transplant product by rejection or 
by the drugs used to control it-whether this be in the 
graft vasculature, drainage system, or any other compo-
nent of the operation-the deadly handmaid of sepsis in 
the associated triad is close by. 
As FK. 506 diffuses into general use. the same practical 
matter will be faced as during the change from azathio-
prine to cyclosporine concerning the difficulty of chang-
ing from a familiar therapeutic regimen to a new one. 
This time around. there will be a better understanding of 
what is involved. The prevention of organ rejection by 
various immunosuppressive agents has been described 
increasingly in terms of the molecular site of disruption 
of the alloactivated T-cell response.4U9 Recent evidence. 
however. suggests that the control of rejection and, ulti-
mately, graft acceptance depend on a permissive effect of 
these drugs on a mutual host-graft leukocyte migration 
that leads in successful cases to mixed. long-term mi-
crochimerism in the recipient and the transplant.'O.51 
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TableS. COX REGRESSION ANALYSIS OF CAUSE OF DEATH AFTER 
UVER TRANSPLANTATION 
FK506 
Pediatnc pabents 203 
No. of mortalities 26 (12.8%) 
Cause of mortality 
Technical failure 6(3.0%) 
Graft failure 7(3.4%) 
Immunosuppression-retated 6(3.0%) 
Disease recurrence 1 (0.5%) 
Extrahepatic event 3(1.5%) 
SepsIs 3 (1.5%) 
Other 0(0.0%) 
AdUt patients 
No. of patients 1188 
No. of mortalities 267(22.5%) 
Cause of mortality 
T echnlCai failure 47(4.0%) 
Graft failure 36(3.0%) 
Immunosuppression-retated 21 (1.8%) 
Disease recurence 54(4.5%) 
Extrahepatic event 34(2.9%) 
Sepsis 58(4.9%) 
Other 17(1.4%) 
• Relative nsk 0' death for pabentS on Cf A compared to pabenls on FK506. 
t Relative nsk adfusted 'or eboIogy 0' anginal cIiseue. age >60 yrs. and UNOS status. 
* Relative nsk adJUIIed for elOogy 01 onginaI Qsease. 
Many of the enigmas of transplantation immunology 
can be explained by the recent discovery of this chime-
rism. The events with immunosuppression leading to the 
ubiquitous persistence of donor leukocytes in recipient 
tissues imply that there is a widespread engagement. ac-
tivation. and inactivation of the immunocytes of both 
donor and recipient ceU populations. and ultimately. the 
development of various degrees of donor specific nonre-
activity. Of critical importance for transplantation of 
leukocyte-rich organs. such as the liver and intestine. re-
cipient-specific nonreactivity of the chimeric donor cells 
also must evolve if the patient is to escape the complica-
tion of graft versus host disease graft versus host disease. 
This fresh insight into the fundamental mechanism of 
allograft acceptance as a two-way immunologic transac-
tion makes comprehensible the characteristic cycle of re-
covery that was first observed in kidney recipients treated 
with azathioprine and prednisone'::o and soon after in re-
cipients of livers and other kinds of organs. Rejection 
that typically occurred in the first few days or weeks 
could be reversed with adrenal conical steroids. and in 
successful cases. most frequently represented in the liver 
recipient population. immunosuppression can be re-
duced and occasionally, stopped.S2 
With this fresh insight into mechanisms. it has become 
Cyclosporine RR- pValue 
241 
90(37.3%) 
33 (13.7%) 4.1998 0.0019 
9(3.7%) 
16(6.6%) 
3(1.2%) 
9(3.7%) 
13 (5.4%) 4.5424t 0.0203 
7 (2.9%) 
971 
372(38.3%) 
58 (6.0ero) 
36(3.7%) 
43(4.4%) 1.9532 0.0173 
84 (8.7%) 1.5942t 0.0108 
49 (5.0ero) 
74(7.6%) 1.5627t 0.0431 
28(2.9%) 
Table 6. CAUSE AND INCIDENCE OF 
RETRANSPLANTATION OF THE PRIMARY 
GRAFT IN FK508 PATIENTS AND 
CYCLOSPORINE PATIENTS WITHIN 3 
MONTHS AFTER UVER TRANSPLANTATION 
FK50I Cyclosporine pYe" 
Pediatnc patients 
No. of patients 203 241 
No. of retransplantatlons 20(9.9%) 55(22.8%) 0.0003 
C8uses 
T echnlCai failure 6(3.0%) 32(13.3%) 0.0001 
Rejection 0 6(2.5%) 0.0240 
Glaft infection 1 (0.5%) 5(2.1%) 0.1500 
Glaft failure 13(6.4%) 12(5.0%) 0.5170 
0iseIIse recurrence 0 0 
Other 0 0 
AcIUt patients 
No. of patients 1188 971 
No. of retranspiantatlOl'ls 118(9.8%) 133(13.7%) 0.0040 
causes 
T echnlCallailure 28(2.4%) 37(3.8%) 0.0490 
Rejection 7 (0.6%) 13(1.3%) 0.0950 
Glaft failure 76(6.4%, 80(8.2%) 0.1000 
Other 2 (0.2'%) 0 0.3nO 
Glaft II'IfecbOn 3(0.3%' 3(0.3%) 0.8040 
0iseIIse recurrence 0 0 
-------- .. -----.----
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Table 7. COX REGRESSION ANALYSIS OF CAUSE OF PRIMARY 
GRAFT RETRANSPLANTAnON 
FlCS06 
Pediatnc pabents 
No. of patients 203 
No. of primary graft retransplantabons 22(10.8%) 
No. of primary graft mortalities 16(7.9%) 
Cause of prmary graft failure 
T ec:hnlcal failure 6(3.0%) 
Graft failure 13(6.4%) 
Rejection 0(0.0%) 
Graft infection 3(1.5%) 
Disease recurrenc e 0(0.0%) 
Other 0(0.0%) 
AdUt patients 
No. of patients. 1188 
No. of primary graft retransplantations 153 (12.9%) 
No. of prvnary graft mortalitieS 197(16.6%) 
Cause of prInary graft failure 
Technical failure 42(3.5%) 
Graft failure 77(6.5%) 
Rejection 18 (1.5%) 
Glatt infection 4(0.3",,0) 
0Iaease rectm1nC8 8(0.7%) 
Other 4(0.3%) 
• Relltive nsk of deaIh for paIIenIS on Of A compared 10 pallenlS on FK506. 
t Relative nsk COUld not be ~ becIuse no evenlS 0CCImId n FK group. 
* Relative nsk IdlUlled for etiology ot ongnaI diseau. age >60. and UNOS status. 
possible to understand the empirically evolved therapeu-
tic dogma on which successful whole organ transplanta-
tion is based. The dogma calls for baseline treatment 
with a maintenance drug or drugs pi us trial-and-error in-
tervention with the highly dose-maneuverable adrenal 
conical steroids to whatever level is required to maintain 
stable graft function. This dogma has been able to ac-
commodate increasingly potent new agents with variable 
sites of action, of which FK 506 is merely the latest ex-
ample. The ease with which FK 506 could be aSsimilated 
into the established strategy was illustrated by our own 
stan-up experience I 7 and by experience in the multicen-
ter trials in which the 28 panicipating teams (10 in Eu-
rope and 18 in the United States) were not permitted to 
have a familiarizing pilot experience with the new agent. 
However, the requisite management skills followed a 
well-worn trail and were acquired so quickly that the 
learning curve was scarcely demonstrable in the better 
::enters. 
Armed now with a drug as potent as FK 506, the same 
generic treatment formula should be applicable to fur-
ther improvements in organ transplantation. If our 
::ontention is valid that the migration and grafting of 
"passenger leukocytes" of bone marrow origin is the 
CycIosporine pVelue 
241 
72(29.9%) 
51 (21.2%) 
35(14_5%) 4.6803 0.0008 
12(5.0%) 
16(6.6%) t 
7(2.9%) 
1 (0.4%) 
1 (0.4%) 
971 
203(20.9%) 
248(25.3%) 
52(5.4%) 
80(8.2%) 
40(4.1%) 2.4431 0.0023 
4(0.4%) 
24(2.5%) 3.5397:1: 0.0022 
3(0.3%) 
seminal explanation for allograft acceptance, the next 
steps will involve manipulation of this process. In a di-
rect extension of the concept, 'J we currently are aug-
menting leukocyte traffic in unconditioned recipients of 
cadaver livers, kidney, hean, and lungs by the concomi-
tant intravenous infusion of donor bone marrow cells 
UDder exactly the same conditions of FK 506-prednisone 
treatment used for the patients of the current repon. 
All 16 of the first organ/bone marrow recipients have 
had good clinical course with follow-ups of S to 16 
months. and all have easily demonstrable chimerism of 
blood mononuclear leukocytes. estimated to 1000 times 
or greater than the naturally occurring low-level chime-
rism. The astonishing ease with which this was accom-
plished without the occurrence of significant clinical 
graft versus host disease has been verification of the new 
paradigm in transplantation immunology and provides 
the first realistic hope that transplantation may become 
feasible. with the ultimate objective of deliberate drug 
discontinuance. 
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Discussion 
DR. GORAN 8. KLINTMALM (Dallas. Texas): You just heard 
another presentation of a monumental piece of work from the 
University of Pittsburgh and the group of Dr. Stanl. We have 
to recall that this drug was discussed at the special meeting in 
Gothenburg in the fall of 1987. Some findings from animal ex-
periments by one of the major investigators. Dr. Roy Caine. 
suggested to us all present that this was too toxic to be used and 
was about to be dropped from the investigator'S table. From 
that meeting Dr. Starzl went home to Pittsburgh and actually 
redid most of the trials that had been presented. Dr. Todo was 
one of the collaborators in the core group and they proved the 
drug to be very potent and very effective. both in the laboratory 
and in the clinical setting. . 
The drug is now poised to be launched as an FDA-approved 
immunosuppressant for liver transplantation in the United 
States. There are other trials going on in kidney transplantation 
as well as in hean and lung transplantation. and hopefully, with 
those concluded we'll see the indications for this drug ex-
panded. Its use for autoimmune disease is a very interesting 
question that will remain to be elucidated. 
The early pilot trials of Pittsburgh called for two large multi-
center trials to be staned. one in Europe and one here in the 
United States. These multi-center trials were done as pros-
pective open-label randomized trials and showed the following 
results: with a minimum of one-and-a-half-yearfollow-up of all 
the patients. the graft and patient survival are the same in the 
FKS06 and in the cyclosporine arms in the U.S. trial. The inci-
dence of rejection is down significantly in the FK grouP. and 
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the use of the rescue agent OKT3 for steroid unresponsive re-
jection is significantly reduced. 
However, what was not anticipated at the onset of the trial 
was that the nephrotoxicity is as serious with FK. as with 
cyciosporine. There's also question about the higher incidence 
of serious neurotoxicity with this drug. This is presently receiv-
ing funher analysis. Finally, FK.S06 seems possibly more dia-
betogenic than cyclosporine. Similar results have been shown 
in the European trials. 
Again. this drug is a major step forward and I think what you 
have seen here on the screen is what happens with improVed 
immunosuppression. It allows the patients to survive the com-
plications that they encounter after liver transplantation. And 
this is vinualIy the same result we saw in 1979 and 1980 when 
we first staned using cyciosporine in Denver. 
If! have any critique, it is why did the Pittsburgh group not 
do a randomized trial in 1991 and have this drug FDA-ap-
proved years ago? You have the patient material and the expe-
rience that equals the rest of the world combined. 
I have. however. a couple of Questions for Dr. Todo. First. 
what do you see as the FK.S06 future role. as a rescue agent. as 
a maintenance immunosuppressant. and in other organ trans-
plantation? And secondly. are there any subgroups of patients 
where you would not use FK.S06 as the primary maintenance 
immunosuppression-for example. patients in acute renal fail-
ure or in patients with hepatic coma prior to transplantation? 
DR. JOSHUA MILLER (Miami. Aorida): I would like to con-
gratulate Dr. Todo and the group headed by Dr. Starzl for in-
troducing this wonderful new agent in transplantation. Dr. 
Todo probably knows that we in Miami have the second biggest 
population of patients convening to FKS06. We have dealt 
with Pittsburgh since 1990 with this agent. I actually do have a 
few points that I would like him to comment on. 
We have noted that when we have referred patients who are 
kidney transplant recipients with refractory rejection for con-
version to FKS06. there is uniformly a stabilization of their 
function and amelioration of what we have termed refractory 
rejection after OKT3 or other agents. These patients have sta-
bilized. yet there appear to be in the primary treatment with 
FK.S06 in Pittsburgh a number of patients who have lost their 
grafts due to rejection. 
It is a difficult thing to bring into balance. because one might 
think that there would even be a group of our patients that 
would prove to be refractory to FKS06 therapy bccauseoftheir 
previous refractory rejection. I think it is almost statistically 
significant now that this is not the case. 
Is there some ki nd of enzyme induction that might go on that 
might make patients who are refractory to Cyclosporine more 
sensitive to FKS06 therapy and vice versa? I think this is an 
interesting biologicaJ question and I would like to have your 
comments on it. 
The other question that I had was on the use of FKS06 in 
children who. in transplants of other organs. are quite subject 
to rejection. even perhaps more so than adults. yet apparently 
your FKS06 therapy in children is more effective than in adults. 
Can you give us a reason for this? 
Again I would like to congratulate Dr. Todo. one ofthe pia-
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neers in the use of this drug both in the experimental animal 
and then in the clinic, for being a major reason why it is now 
virtually on our pharmacy shelves. 
DR. JOHN TERBlANCHE (Cape Town. South Africa): Could 
you tell us what the relative costs are going to be vis-a-vis the 
previous agents? The problem we have outside the United 
States-and I think you may actually have it here as well-is 
cost. 
Our cardiac transplants in Cape Town are limited by the cost 
of the current drugs, our liver transplants are limited in the 
same way, and we in fact convert the kidney transplants to Im-
uran after 6 months, because cost is a problem. What will the 
cost ofFK506 be? Is it going to be a problem? Or has the com-
pany kept the cost a secret? 
DR. CHARLES MILLER (Mount Sinai Hospital. New York): I 
would like to congratulate Dr. Todo on a beautiful piece of 
work. 
I noticed one point of real interest, that part of the improved 
survival was due to a decrease in recurrence of primary disease. 
And one question would be, are these primary diseases autoim-
mune-type disease such as autoimmune hepatitis. primary bil-
iary cirrhosis or sclerosing cholangitis. or is it in fact a decrease 
in recurrent infectious disease such as hepatitis C or hepatitis 
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We have found that there has been a correlation between re-
current viral disease and the amount of rejection and/or im-
munosuppression you need to use. and I wonder if FK506 by 
preventing rejection has reduced those recurrent infections that 
are so problematic? 
I congratulate you again on a beautiful presentation. 
DR. SATORU Toco (Oosing discussion): Thank you very 
much for your comments. Dr. Klintmalm and Dr. Joshua Mil-
ler. Dr. Terblanche and Dr. Charlie Miller. 
Regarding the first question from Dr. Klintmalm. whether 
FKS06 should be used for rescue therapy or for primary immu-
nosuppression. I believe it should be both. From our ex peri-
ence. as I have shown in this paper. patients on this agent have 
a much greater chance of survival after liver transplantation 
than with any other conventional treatment. It is particularly 
so with pediatric recipients. Infants and children are greatly 
benefitted by the use of FK506 in terms of patient survival. 
graft survival. rejection episodes. and the need for other anti-
rejection drug usage, especially steroids. This means that 
FKS06 should be used as a baseline immunosuppressive agent. 
In addition. as shown by us and others. many of the recipients 
who developed intractable rejection or side effects with conven-
tional therapy were successfully rescued by FKS06. Thus. this 
agent should also be used as a rescue therapy. The potent im-
munosuppressive effect of FK506 is readily ascertained by the 
fact that intestinal transplantation in humans. which has never 
been satisfactory with conventional treatment, has become a 
practical reality with the advent of this agent. 
I don't believe that any subgroup of patients should be elim-
inated from treatment with FKS06. since most of the side 
effects of FKS06 are equal to or less than conventional agents. 
and, I believe, liver recipients should be offered a better chance 
of survival after life-saving surgery. 
Dr. Joshua Miller. we are not sure why pediatric patients 
have much better results than adult recipients. Since they can 
tolerate higher doses ofFKS06. the higher initial concentration 
of this agent in plasma may permit better control of graft rejec-
tion. 
Reprding the question from Dr. Terblanche about the cost 
ofFK506, I hear from the Fujisawa Pharmaceutical Company 
that it would be similar to conventional agents. However. in a 
clinical setting, since this agent allows earlier discharge of the 
recipient after liver transplantation. a lower incidence ofrejec-
tion episodes. less frequent use of other anti-rejection agents. 
and fewer retransplantations and lower mortality rates, it offers 
better cost-performance. 
Finally, in answer to the question from Dr. Charlie Miller 
why FK506 was associated with a lower incidence of recurrent 
liver disease. as described in this paper. strict selection for liver 
transplantation of patients who have hepatitis 8 virus related 
liver disease is a major reason for the reduction. 
